Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC-HIVDNA009-00-VP in Acute HIV Infection
NCT00125099Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VRC-HIVDNA009-00-VP in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Grade 3 or 4 sign/symptom, laboratory abnormality, or death, Viral Load Rebound and 2 more. Status: completed.
02
Drugs
VRC-HIVDNA009-00-VP
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00125099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125099.